Top 20 of Lymphoma, Non-Hodgkin

Article title # Publications/# Citations

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

1995: ECesarman; YChang; DMKnowles; PSMoore; JWSaid;

639

Flexible regression models with cubic splines.

1989: SDurrleman; RSimon;

292

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

1999: JOArmitage; FCabanillas; GPCanellos; WCarter; RCastellino; BDCheson; BCoiffier; JMConnors; ... RIFisher; AGrillo-Lopez; AHagenbeek; NLHarris; WHiddemann; RHoppe; SJHorning; DKlippensten; TALister; MAShipp; JVose;

277

Revised response criteria for malignant lymphoma.

2007: International Harmonization Project on Lymphoma; BDCheson; BCoiffier; JMConnors; VDiehl; MDreyling; MFederico; RIFisher; ... RDGascoyne; AHagenbeek; RTHoppe; SJHorning; MEJuweid; TALister; BPfistner; STRosen; LSpecht; SStroobants; KTobinai; JMVose; EZucca;

274

Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice.

2006: SCostinean; CMCroce; NHeerema; YPekarsky; ETili; SVolinia; NZanesi;

273

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.

1993:

270

Helicobacter pylori infection and gastric lymphoma.

1994: GDFriedman; ABGelb; SHansen; EJellum; NOrentreich; JParsonnet; LRodríguez; JHVogelman; RAWarnke;

266

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998: IBence-Bruckler; FCabanillas; MSCzuczman; BKDallaire; AJGrillo-López; MRHeyman; ADHo; VJain; ... RLévy; BKLink; JLister; PMcLaughlin; DShen; KWey; CAWhite; MEWilliams;

214

Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.

1993: Mde Boni; TCDiss; CDoglioni; PGIsaacson; AMoschini; LPan; ACWotherspoon;

197

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

2011: SBen-Neriah; IBirol; MBoyle; ABrooks-Wilson; YButterfield; SChan; SChittaranjan; RChiu; ... JMConnors; RDCorbett; ADelaney; MField; MRFirme; RDGascoyne; RGoya; MGriffith; MHirst; RHolt; DEHorsman; SJackman; NAJohnson; SJJones; MKrzywinski; SLi; MAMarra; HMcDonald; BMeissner; MMendez-Lago; IMMeyer; MMoksa; RMoore; RDMorin; AJMungall; KLMungall; LRimsza; SRogic; JSchein; DWScott; TMSeverson; DSmailus; JJSpinelli; ATam; JTamura-Wells; DLTrinh; KTse; BWoolcock; OYakovenko; TZeng; EYZhao; YZhao;

195

The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.

1997: AAiuti; CBleul; JCGutierrez-Ramos; TSpringer; IJWebb;

185

The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.

1995: ISChen; MLChen; JBJowett; VPlanelles; BPoon; NPShah;

175

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

1997:

163

Trends in cancer risk among people with AIDS in the United States 1980-2002.

2006: HIV/AIDS Cancer Match Study; RJBiggar; EAEngels; JJGoedert; TSMcNeel; RMPfeiffer; SMScoppa; PVirgo;

150

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

2005: Swiss HIV Cohort; ABordoni; GMClifford; LDal Maso; Dde Weck; TFisch; SFranceschi; GJundt; ... OKeiser; AKofler; FLevi; JPolesel; ERapiti; MRickenbach;

142

Cancer risk in people infected with human immunodeficiency virus in the United States.

2008: RJBiggar; HCross; ACrutchfield; EAEngels; JLFinch; JJGoedert; RGrigg; HIHall; ... THylton; TSMcNeel; KSPawlish;

140

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

2006: MabThera International Trial Group; CCorrado; DGill; MHansen; KImrie; UJaeger; EKuhnt; SKvaloy; ... TLehtinen; MLoeffler; ALópez-Guillermo; DMa; MMendila; NMilpied; AÖsterborg; RPettengell; MPfreundschuh; MRashford; AScheliga; OShpilberg; RStahel; MTrneny; LTrümper; JWalewski; PLZinzani;

133

Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

1995: MPAndrich; MRBrown; CCChen; IMFeuerstein; TAFleisher; MEHorowitz; CLMackall; ITMagrath; ATShad; SMSteinberg;

130

Molecular thanatopsis: a discourse on the BCL2 family and cell death.

1996: SJKorsmeyer; EYang;

129

Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

1990: DMBarnes; RCamplejohn; RDover; CEGillett; PAHall; DBKellock; DALevison; JAWatkins; ALWoods; CCYu;

118